The complexities in system building strategies — The case of personalized cancer medicines in England
Authors:
- P. KukkPKP. Kukk
- E.H.M. MoorsEME.H.M. Moors
- M.P. HekkertMHM.P. Hekkert
- 1 September 2015
- journal article
- Published by Elsevier in Technological Forecasting and Social Change
- Vol. 98, 47-59
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Creating and shaping innovation systems: Formal networks in the innovation system for stationary fuel cells in GermanyEnergy Policy, 2011
- Understanding the build-up of a technological innovation system around hydrogen and fuel cell technologiesInternational Journal of Hydrogen Energy, 2009
- Opportunities for and limits to Academics as System builders—The case of realizing the potential of gasified biomass in AustriaEnergy Policy, 2009
- HER2 testing in the UK: consensus from a national consultationJournal of Clinical Pathology, 2007
- Explaining the failure of the Dutch innovation system for biomass digestion—A functional analysisEnergy Policy, 2007
- Recommendations for HER2 testing in the UKJournal of Clinical Pathology, 2000
- On the nature, function and composition of technological systemsJournal of Evolutionary Economics, 1991
- First-mover advantagesStrategic Management Journal, 1988
- Emerging Industries and the Burnout of Pioneers*Journal of Product Innovation Management, 1986